Download PDF
Drug Res (Stuttg) 2019; 69(02): 83-92
DOI: 10.1055/a-0643-4604
Original Article
© Georg Thieme Verlag KG Stuttgart · New York

Taurine Ameliorates Thyroid Hypofunction and Renal Injury in L-NAME-Induced Hypertensive Rats

Isaac A. Adedara
1   Drug Metabolism and Toxicology Research Laboratories, Department of Biochemistry, College of Medicine, University of Ibadan, Ibadan, Nigeria
,
Sanmi E. Alake
1   Drug Metabolism and Toxicology Research Laboratories, Department of Biochemistry, College of Medicine, University of Ibadan, Ibadan, Nigeria
,
Laide O. Olajide
1   Drug Metabolism and Toxicology Research Laboratories, Department of Biochemistry, College of Medicine, University of Ibadan, Ibadan, Nigeria
,
Mercy O. Adeyemo
1   Drug Metabolism and Toxicology Research Laboratories, Department of Biochemistry, College of Medicine, University of Ibadan, Ibadan, Nigeria
,
Temitayo O. Ajibade
2   Department of Veterinary Physiology, Biochemistry and Pharmacology, Faculty of Veterinary Medicine, University of Ibadan, Nigeria
,
Ebenezer O. Farombi
1   Drug Metabolism and Toxicology Research Laboratories, Department of Biochemistry, College of Medicine, University of Ibadan, Ibadan, Nigeria
› Author Affiliations
Further Information

Publication History

received 07 February 2018

accepted 12 June 2018

Publication Date:
11 July 2018 (online)

Also available at
    Permissions and Reprints

Abstract

There is a growing global interest in hypertension due to its associated complications including renal dysfunction in patients. The thyroid system reportedly regulates renal function in both animal and human. The present study investigated the therapeutic efficacy of taurine on renal and thyroid dysfunctions in hypertensive rats. Hypertension was induced by oral administration of nitric oxide synthase inhibitor, N-nitro L-arginine-methyl-ester (L-NAME), at 40 mg/kg body weight to the male Wistar rats for 14 consecutive days. The hypertensive rats were subsequently treated with either taurine (100 and 200 mg/kg) or reference drug atenolol (10 mg/kg) for another 14 consecutive days. Hypertensive rats showed renal damage evidenced by elevated plasma creatinine and urea levels when compared with normotensive control rats. Furthermore, L-NAME-induced hypertensive rats showed decreased circulatory concentrations of thyroid stimulating hormone, thyroxine, triiodothyronine and the ratio of triiodothyronine to thyroxine. The marked decrease in the renal antioxidant enzyme activities and nitric oxide level was accompanied by significant increase in myeloperoxidase activity and biomarkers of oxidative stress in hypertensive rats. Histological examination of kidneys from hypertensive rats revealed congestion of blood vessels, hemorrhagic lesion and disorganized glomerular structure. However, treatment with taurine or atenolol significantly reversed the suppression of thyroid function, ameliorated renal oxidative stress and histopathological lesions in L-NAME-induced hypertensive rats. Taurine may be a useful chemotherapeutic supplement in enhancing renal and thyroid functions in hypertensive patients.

Key words

Hypertension - taurine - renal injury - thyroid function - rats
 

  • References

  • 1 Sternlicht H, Bakris GL. The kidney in hypertension. Med Clin North Am 2017; 101: 207-217
    CrossrefPubMedGoogle Scholar
  • 2 United States Renal Data System . Annual data report. Incidence and prevalence of ESRD. Am J Kidney Dis 1997; 30: S40-S53
    CrossrefPubMedGoogle Scholar
  • 3 Axon RN, Turner M, Buckley R. An Update on inpatient hypertension management. Curr Cardiol Rep 2015; 17: 94
    CrossrefPubMedGoogle Scholar
  • 4 Roszkowska-Blaim M, Skrzypczyk P. Hypertension in children with end-stage renal disease. Adv Med Sci 2015; 60: 342-348
    CrossrefPubMedGoogle Scholar
  • 5 Hsu CY, McCulloch CE, Darbinian J. et al. Elevated blood pressure and risk of end-stage renal disease in subjects without baseline kidney disease. Arch Intern Med. 2005; 165: 923-928
    CrossrefPubMedGoogle Scholar
  • 6 National Institute of Diabetes and Digestive and Kidney Diseases . United States renal data system 2012 annual data report: Volume 2: Atlas of end-stage renal disease in the United States. Washington, D.C.: U.S. Government Printing Office; 2012. Report
    Google Scholar
  • 7 Kabedi NN, Mwanza JC, Lepira FB. et al. Hypertensive retinopathy and its association with cardiovascular, renal and cerebrovascular morbidity in Congolese patients. Cardiovasc J Afr 2014; 25: 228-232
    CrossrefPubMedGoogle Scholar
  • 8 Nansseu JR, Noubiap JJ, Mengnjo MK. et al. The highly neglected burden of resistant hypertension in Africa: A systematic review and meta-analysis. BMJ Open 2016; 6: e011452
    CrossrefPubMedGoogle Scholar
  • 9 Marín R, Gorostidi M, Fernández-Vega F. et al. Systemic and glomerular hypertension and progression of chronic renal disease: The dilemma of nephrosclerosis. Kidney Int 2005; 99: S52-S56
    PubMedGoogle Scholar
  • 10 Nosalski R, McGinnigle E, Siedlinski M. et al. Novel immune mechanisms in hypertension and cardiovascular risk. Curr Cardiovasc Risk Rep 2017; 11: 12
    CrossrefPubMedGoogle Scholar
  • 11 Touyz RM. Reactive oxygen species, vascular oxidative stress, and redox signaling in hypertension: What is the clinical significance?. Hypertension 2004; 44: 248-252
    CrossrefPubMedGoogle Scholar
  • 12 Redon J, Oliva MR, Tormos C. et al. Antioxidant activities and oxidative stress byproducts in human hypertension. Hypertension 2003; 41: 1096-1101
    CrossrefPubMedGoogle Scholar
  • 13 Dikalov SI, Dikalova AE. Contribution of mitochondrial oxidative stress to hypertension. Curr Opin Nephrol Hypertens. 2016; 25: 73-80
    CrossrefPubMedGoogle Scholar
  • 14 Kaptein EM. Thyroid hormone metabolism and thyroid diseases in chronic renal failure. Endocr Rev 1996; 17: 45-63
    CrossrefPubMedGoogle Scholar
  • 15 Iglesias P, Díez JJ. Thyroid dysfunction and kidney disease. Euro J Endocrinol 2009; 160: 503-515
    CrossrefPubMedGoogle Scholar
  • 16 Rhee CM. The interaction between thyroid and kidney disease: An overview of the evidence. Curr Opin Endocrinol Diabetes Obes 2016; 23: 407-415
    CrossrefPubMedGoogle Scholar
  • 17 Den Hollander JG, Wulkan RW, Mantel MJ. et al. Correlation between severity of thyroid dysfunction and renal function. Clin Endocrinol 2005; 62: 423-427
    CrossrefPubMedGoogle Scholar
  • 18 Gopinath B, Harris DC, Wall JR. et al. Relationship between thyroid dysfunction and chronic kidney disease in community-dwelling older adults. Maturitas 2013; 75: 159-164
    CrossrefPubMedGoogle Scholar
  • 19 Vargas F, Moreno JM, Rodríguez-Gómez I. et al Vascular and renal function in experimental thyroid disorders. Eur J Endocrinol. 2006; 154: 197-212
    CrossrefPubMedGoogle Scholar
  • 20 Morgado E, Neves PL. Hypertension and chronic kidney disease: Cause and consequence – Therapeutic considerations, antihypertensive drugs, Prof. Hossein Babaei (Ed.), ISBN: 978-953-51-0462-9, InTech; 2012;
    PubMed
  • 21 Huxtable RJ. The physiological actions of taurine. Physiol Rev 1992; 72: 101-163
    CrossrefPubMedGoogle Scholar
  • 22 Das J, Roy A, Sil PC. Mechanism of the protective action of taurine in toxin and drug induced organ pathophysiology and diabetic complications: A review. Food Funct 2012; 3: 1251-1264
    CrossrefPubMedGoogle Scholar
  • 23 Adedara IA, Abolaji AO, Idris UF. et al. Neuroprotective influence of taurine on fluoride-induced biochemical and behavioral deficits in rats. Chem Biol Interact 2017; 261: 1-10
    CrossrefPubMedGoogle Scholar
  • 24 De Luca A, Pierno S, Camerino DC. Taurine: The appeal of a safe amino acid for skeletal muscle disorders. J Transl Med 2015; 13: 243-251
    CrossrefPubMedGoogle Scholar
  • 25 Xu YJ, Arneja AS, Tappia PS. et al. The potential health benefits of taurine in cardiovascular disease. Exp Clin Cardiol 2008; 13: 57-65
    PubMedGoogle Scholar
  • 26 Hu J, Xu X, Yang J. et al. Antihypertensive effect of taurine in rat. Adv Exp Med Biol 2009; 643: 75-84
    PubMedGoogle Scholar
  • 27 Shao A, Hathcock JN. Risk assessment for the amino acids taurine, L-glutamine and L-arginine. Regul Toxicol Pharmacol 2008; 50: 376-399
    CrossrefPubMedGoogle Scholar
  • 28 Yamori Y, Taguchi T, Hamada A. et al. Taurine in health and diseases: Consistent evidence from experimental and epidemiological studies. J Biomed Sci. 2010; 17: S6
    CrossrefPubMedGoogle Scholar
  • 29 Roysommuti S, Suwanich A, Jirakulsomchok D. et al. Perinatal taurine depletion increases susceptibility to adult sugar-induced hypertension in rats. Adv Exp Med Biol 2009; 643: 123-133
    PubMedGoogle Scholar
  • 30 Rahman MM, Park HM, Kim SJ. et al. Taurine prevents hypertension and increases exercise capacity in rats with fructose-induced hypertension. Am J Hypertens 2011; 24: 574-581
    CrossrefPubMedGoogle Scholar
  • 31 Cardoso AM, Abdalla FH, Bagatini MD. et al. Swimming training prevents alterations in acetylcholinesterase and butyryl cholinesterase activities in hypertensive rats. Am J Hypertens 27 2014; 522-529
    CrossrefPubMedGoogle Scholar
  • 32 Akinyemi AJ, Adedara IA, Thome GR. et al. Dietary supplementation of ginger and turmeric improves reproductive function in hypertensive male rats. Toxicol Rep 2015; 2: 1357-1366
    PubMedGoogle Scholar
  • 33 National Research Council . Guide for the Care and Use of Laboratory Animals. Washington: National Academies Press; 2011
    Google Scholar
  • 34 Talas ZS. Propolis reduces oxidative stress in L-NAME-induced hypertension rats. Cell Biochem Funct 2014; 32: 150-154
    CrossrefPubMedGoogle Scholar
  • 35 Adedara IA, Alake SE, Adeyemo MO. et al. Taurine enhances spermatogenic function and antioxidant defense mechanisms in testes and epididymis of L-NAME-induced hypertensive rats. Biomed Pharmacother 2018; 97: 181-189
    CrossrefPubMedGoogle Scholar
  • 36 Bradford MM. A rapid and sensitive for the quantitation of microgram quantitites of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-254
    CrossrefPubMedGoogle Scholar
  • 37 Misra HP, Fridovich I. The role of superoxide anion in the autooxidation of epinephrine and a simple assay for superoxide dismutase. J Biol Chem 1972; 247: 3170-3175
    CrossrefPubMedGoogle Scholar
  • 38 Clairborne A. Catalase activity. In: Greewald AR. (ed.) Handbook of Methods for oxygen radical research. Boca Raton, FL: CRC Press; 1995. pp 237-242
    Google Scholar
  • 39 Jollow DJ, Mitchell JR, Zampaglione N. et al. Bromobenzene induced liver necrosis: Protective role of glutathione and evidence for 3, 4 bromobenzene oxide as the hepatotoxic metabolite. Pharmacology 1974; 11: 151-169
    CrossrefPubMedGoogle Scholar
  • 40 Rotruck JT, Pope AL, Ganther HE. et al. Selenium: Biochemical role as a component of glutathione peroxidase. Science 1973; 179: 588-590
    CrossrefPubMedGoogle Scholar
  • 41 Wolff SP. Ferrous ion oxidation in the presence of ferric ion indicator xylenol orange for measurement of hydroperoxides. Methods Enzymol 1994; 233: 182-189
    PubMedGoogle Scholar
  • 42 Farombi EO, Tahnteng JG, Agboola AO. et al. Chemoprevention of 2-acetylaminofluorene-induced hepatotoxicity and lipid peroxidation in rats by kolaviron-a Garcinia kola seed extract. Food Chem Toxicol 2000; 38: 353-541
    PubMedGoogle Scholar
  • 43 Granell S, Gironella M, Bulbena O. et al. Heparin mobilizes xanthine oxidase and induces lung inflammation in acute pancreatitis. Crit Care Med 2003; 31: 525-530
    CrossrefPubMedGoogle Scholar
  • 44 Green LC, Wagner DA, Glogowski J. et al. Analysis of nitrate, nitrite and [15 N] nitrate in biological fluids. Anal Biochem 1982; 126: 131-138
    CrossrefPubMedGoogle Scholar
  • 45 Bancroft JD, Gamble M. Theory and practice of histology techniques. 6th edition Churchill Livingstone Elsevier; 2008. pp 83 - 134
    Google Scholar
  • 46 Whitworth JA. Progression of Renal Failure – The Role of Hypertension. Ann Acad Med Singapore 2005; 34: 8-15
    PubMedGoogle Scholar
  • 47 Silambarasan T, Manivannan J, Raja B. et al. Prevention of cardiac dysfunction, kidney fibrosis and lipid metabolic alterations in L-NAME hypertensive rats by sinapic acid – Role of HMG-CoA reductase. Eur J Pharmacol. 2016; 777: 113-123
    CrossrefPubMedGoogle Scholar
  • 48 Rajeshwari T, Raja B, Manivannan J. et al. Valproic acid prevents the deregulation of lipid metabolism and renal renin-angiotensin system in L-NAME induced nitric oxide deficient hypertensive rats. Environ Toxicol Pharmacol. 2014; 37: 936-945
    CrossrefPubMedGoogle Scholar
  • 49 Adedara IA, Teberen R, Ebokaiwe AP. et al. Induction of oxidative stress in liver and kidney of rats exposed to Nigerian bonny light crude oil. Environ Toxicol 2012; 27: 372-379
    CrossrefPubMedGoogle Scholar
  • 50 Fonseca TL, Correa-Medina M, Campos MP. et al. Coordination of hypothalamic and pituitary T3 production regulates TSH expression. J Clin Invest 2013; 123: 1492-1500
    CrossrefPubMedGoogle Scholar
  • 51 Gereben B, Zavacki AM, Ribich S. et al. Cellular and molecular basis of deiodinase-regulated thyroid hormone signaling. Endocr Rev 2008; 29: 898-938
    CrossrefPubMedGoogle Scholar
  • 52 Fellet AL, Arza P, Arreche N. et al. Nitric oxide and thyroid gland: Modulation of cardiovascular function in autonomic-blocked anaesthetized rats. Exp Physiol 2004; 89: 303-312
    CrossrefPubMedGoogle Scholar
  • 53 Montenegro J, Gonzalez O, Saracho R. et al. Changes in renal function in primary hypothyroidism. Am J Kidney Dis 1996; 27: 195-198
    CrossrefPubMedGoogle Scholar
  • 54 Gardiner SM, Compton AM, Bennett T. et al. Control of regional blood flow by endothelium-derived nitric oxide. Hypertension 1990; 15: 486-492
    CrossrefPubMedGoogle Scholar
  • 55 Kato Y. Neutrophil myeloperoxidase and its substrates: Formation of specific markers and reactive compounds during inflammation. J Clin Biochem Nutr. 2016; 58: 99-104
    CrossrefPubMedGoogle Scholar
  • 56 Rosen H, Crowley JR, Heinecke JW. Human neutrophils use the myeloperoxidase hydrogen peroxide-chloride system to chlorinate but not nitrate bacterial proteins during phagocytosis. J Biol Chem 2002; 277: 30463-30468
    CrossrefPubMedGoogle Scholar
  • 57 Berkels R, Egink G, Marsen TA. et al. Nifedipine Increases endothelial nitric oxide bioavailability by antioxidative mechanisms. Hypertension 2001; 37: 240-245
    CrossrefPubMedGoogle Scholar
  • 58 Mihalj M, Tadzic R, Vcev A. et al. Blood pressure reduction is associated with the changes in oxidative stress and endothelial activation in hypertension, regardless of antihypertensive therapy. Kidney Blood Press Res 2016; 41: 721-735
    CrossrefPubMedGoogle Scholar
  • 59 Reis GS, Augusto VS, Silveira AP. et al. Oxidative-stress biomarkers in patients with pulmonary hypertension. Pulm Circ 2013; 3: 856-861
    CrossrefPubMedGoogle Scholar
  • 60 Dekleva M, Lazic JS, Arandjelovic A. et al. Beneficial and harmful effects of exercise in hypertensive patients: the role of oxidative stress. Hypertens Res 2017; 40: 15-20
    CrossrefPubMedGoogle Scholar
  • 61 Rajeshwari T, Raja B, Manivannan J. et al. Valproic acid prevents the deregulation of lipid metabolism and renal renin-angiotensin system in L-NAME induced nitric oxide deficient hypertensive rats. Environ Toxicol Pharmacol 2014; 37: 936-945
    CrossrefPubMedGoogle Scholar
  • 62 Kashyap S, Boyilla R, Zaia PJ. et al. Development of renal atrophy in murine 2 kidney 1 clip hypertension is strain independent. Res Vet Sci 2016; 107: 171-177
    CrossrefPubMedGoogle Scholar